Document is current
Any future updates will be listed below
-
Authors
Bojti, Istvan
Przewosnik, Anne-Sophie
Luxenburger, Hendrik
Hofmann, Maike
Neumann-Haefelin, Christoph
Esser, Jennifer S.
Siegel, Patrick M.
Maier, Alexander
Kovacs, Sarolta Bojtine
Kardos, Laszlo
Csanádi, Zoltan
Rieder, Marina
Duerschmied, Daniel
Lother, Achim
Bode, Christoph
Szabó, Gabor Tamas
Czuriga, Daniel
-
Clinical Trials BETA
Clinical trials referenced in this document:
drks00026655 at German Clinical Trials RegisterDocuments that mention this clinical trial
Decreased level of serum NT-proCNP associates with disease severity in COVID-19
https://doi.org/10.1186/s12931-023-02469-4
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1425, SFB1425)
German Center for Infection Research and the Federal Ministry of Education and Research, Germany (8039801926)
Universitäts-Herzzentrum Freiburg - Bad Krozingen GmbH
- License Information
-
More Information
Article History
Received: 18 July 2022
Accepted: 5 June 2023
First Online: 29 June 2023
Change Date: 28 July 2023
Change Type: Update
Change Details: Figure 3 heading and X axis have been corrected.
Declarations
:
: Experiments involving human samples were approved by the institutional review board of the University of Freiburg, Germany (Nr: 21-1259). Written informed consent was obtained from the patients.
: Not applicable.
: The authors declare that they have no competing interests.
